Corrigendum to 'Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: effects on weight loss and safety in adults with overweight or obesity' [Mol Metab 78 (2023) 101801]

Autor: Martin Haljeta Friedrichsen, Lars Endahl, Frederik Flindt Kreiner, Ronald Goldwater, Martin Kankam, Søren Toubro, Sune Boris Nygård

Publikováno v: Molecular Metabolism, Vol 89, Iss , Pp 102023- (2024)

Externí odkaz: https://doaj.org/article/a2cb6b12f7a44bd6b4923aaac9fbb43b

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

Autor: Jena S. Tronieri, Anthony N. Fabricatore, Thomas A. Wadden, Pernille Auerbach, Lars Endahl, Danny Sugimoto, Domenica Rubino

Publikováno v: Obesity Facts, Pp 1-12 (2020)

Introduction: Individuals who enroll in intensive behavioral therapy (IBT) programs are asked to make several lifestyle changes simultaneously. However, few studies have examined the relative effects of adherence to different treatment components on

Externí odkaz: https://doaj.org/article/aaa1ff0326af4e3b81c7284095a98686

Estimating and reporting treatment effects in clinical trials for weight management: using estimands to interpret effects of intercurrent events and missing data

Autor: Lars Endahl, Michael E. J. Lean, Dorthe Skovgaard, John P.H. Wilding, Sean Wharton, Thomas A. Wadden, Altynai Satylganova, Arne Astrup

Publikováno v: International Journal of Obesity (2005)
Wharton, S, Astrup, A, Endahl, L, Lean, M E J, Satylganova, A, Skovgaard, D, Wadden, T A & Wilding, J P H 2021, ' Estimating and reporting treatment effects in clinical trials for weight management: Using estimands to interpret effects of intercurrent events and missing data ', International Journal of Obesity, vol. 45, pp. 923-933 . https://doi.org/10.1038/s41366-020-00733-x

In the approval process for new weight management therapies, regulators typically require estimates of effect size. Usually, as with other drug evaluations, the placebo-adjusted treatment effect (i.e., the difference between weight losses with pharma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccdf0a191d8b0b56f5f155b194c7823a
http://europepmc.org/articles/PMC8081661

Effects of Dietary Self-Monitoring, Physical Activity, Liraglutide 3.0 mg, and Placebo on Weight Loss in the SCALE IBT Trial

Autor: Lars Endahl, Jena Shaw Tronieri, Thomas A. Wadden, Anthony N. Fabricatore, Domenica Rubino, Pernille Auerbach, Danny Sugimoto

Publikováno v: Obesity Facts, Pp 1-12 (2020)
Obes Facts

Introduction: Individuals who enroll in intensive behavioral therapy (IBT) programs are asked to make several lifestyle changes simultaneously. However, few studies have examined the relative effects of adherence to different treatment components on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25c01460f7880e79278d4766f1a16189
https://www.karger.com/Article/FullText/511130

SAT-105 Weight Loss As Determined By Adherence To Reduced Caloric Diet, Increased Physical Activity, Liraglutide 3.0 Mg and Placebo: A Sub-analysis Of The SCALE IBT Trial

Autor: Lars Endahl, Domenica Rubino, Jena Shaw Tronieri, Michael T. Lund, Thomas A. Wadden, Pernille Auerbach, Daniel Sugimoto

Publikováno v: Journal of the Endocrine Society

Liraglutide 3.0 mg is approved by the Food and Drug Administration for chronic weight management in the United States as an adjunct to reduced caloric diet and increased physical activity. The objective of the SCALE IBT trial (NCT02963935) was to com

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d044a3802e6754073e73bb3d2c549146
https://doi.org/10.1210/js.2019-sat-105